Financials data is unavailable for this security.
View more
Year on year GlaxoSmithKline Pharmaceuticals Ltd had net income fall -3.39% from 6.11bn to 5.90bn despite revenues that grew 6.21% from 32.52bn to 34.54bn over the same period.
| Gross margin | 61.70% |
|---|---|
| Net profit margin | 18.96% |
| Operating margin | 22.48% |
| Return on assets | 19.24% |
|---|---|
| Return on equity | 42.03% |
| Return on investment | 36.09% |
More ▼
Cash flow in INRView more
In 2024, GlaxoSmithKline Pharmaceuticals Ltd increased its cash reserves by 83.66%, or 292.30m. The company earned 5.82bn from its operations for a Cash Flow Margin of 16.85%. In addition the company generated 87.12m cash from investing, though they paid out 5.61bn more in financing than they received.
| Cash flow per share | 43.71 |
|---|---|
| Price/Cash flow per share | 53.99 |
| Book value per share | 98.74 |
|---|---|
| Tangible book value per share | 97.66 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.66 |
|---|---|
| Quick ratio | 1.38 |
| Total debt/total equity | 0.0088 |
|---|---|
| Total debt/total capital | 0.0088 |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -2.91%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.94% |
|---|---|
| Div growth rate (5 year) | 9.86% |
| Payout ratio (TTM) | 80.31% |
| EPS growth(5 years) | 5.78 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 3.57 |
More ▼
